Therapeutic potential of policosanol in the concurrent management of dyslipidemia and non-alcoholic fatty liver disease

• Published in: Future journal of pharmaceutical sciences 2022-01, Vol.8 (1), p.1-9, Article 11
• Main Authors: Arora, Mandeep K., Pandey, Sudhanshu, Tomar, Ritu, Sahoo, Jagannath, Kumar, Dinesh, Jangra, Ashok
• Format: Article
• Language: English
• Subjects: Acids; Animals; Atorvastatin; Cardiovascular disease; Cholesterol; Diabetes; Drinking water; Hepatotoxicity; High density lipoprotein; Lipid peroxidation; Lipids; Lipoproteins; Liver diseases; Medicine; Medicine & Public Health; Metabolic disorders; Oxidative stress; Pharmaceutical sciences; Policosanol; Reagents; Silymarin; Statins
• ISSN: 2314-7253; 2314-7245; 2314-7253
• DOI: 10.1186/s43094-022-00399-4

Background High-fat diet (HFD) possesses a major cause of cardiovascular disease, and hepatosteatosis. Unfortunately, long-term use of statins has a theoretical possibility of worsening of hepatic histology in the patients with non-alcoholic fatty liver disease (NAFLD). The objective of the study was to explore hepatoprotective potential of policosanol as an alternative to statins in experimental NAFLD. For the same, young male Wistar rats were fed with HFD for 8 weeks to induce NAFLD. 48 adult Wistar rats were distributed into six investigational groups: normal control, HFD control, and four treatment groups, receiving policosanol (50 and 100 mg/kg/day), atorvastatin (30 mg/kg/day), and silymarin (100 mg/kg/day) for 8 weeks along with HFD. Result HFD consumption caused profound hepatotoxicity evident by hepatic oxidative stress, increased Serum glutamic oxaloacetic transaminase (SGOT), Serum glutamic pyruvic transaminase (SGPT), Alkaline phosphatase (ALP), and bilirubin content. Treatment with policosanol (100 mg/kg) markedly reduced the elevated SGOT, SGPT, and ALP levels in HFD-fed rats. Moreover, policosanol significantly reduced hepatic oxidative stress manifest by reduced malondialdehyde (MDA) and increased glutathione (GSH) level. The treatment with policosanol (100 mg/kg) was found to be more active in attenuating the HFD-induced hepatotoxicity as compared to policosanol (50 mg/kg) and atorvastatin (30 mg/kg). Moreover, we observed that the hepatoprotective potential of policosanol was comparable to the silymarin. Conclusions The results of the study clearly indicated that the policosanol could be considered an intriguing approach for the treatment of NAFLD.